SAFE HARBOR

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These uncertainties may cause our actual future results to be materially different than those expressed in our forward looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.
## Leveraging Global Scale & Capabilities

Working **collaboratively & urgently** across Segments, Global Operations, R&D, and Regulatory to manage a complex and shifting **regulatory, supply chain, and logistics environment**

<table>
<thead>
<tr>
<th>Priorities</th>
<th>Response</th>
<th>Ramp</th>
<th>Redundancy</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approach</strong></td>
<td>Globally serve customers with the <strong>broadest, high-quality COVID-19 offerings</strong> with relevant regulatory approvals</td>
<td>Increase manufacturing from <strong>zero to millions of tests per week</strong></td>
<td>Develop <strong>redundancy in R&amp;D, supply, and manufacturing bases</strong></td>
<td>✓ Well positioned to drive positive outcomes and support global needs</td>
</tr>
<tr>
<td></td>
<td>Mobilized employee health &amp; safety measures and cross-functional teams prioritized &amp; aligned by segment leadership</td>
<td>Implemented multi-site plans: supplier ramps, site staffing &amp; protocols, logistics, and customer support</td>
<td>Developed alternative designs to enable scale &amp; mitigate supply, regulatory &amp; logistics risks</td>
<td>✓ Making an impact for our customers and the quality of testing they provide to patients</td>
</tr>
</tbody>
</table>

All while putting **safety first** by implementing measures to limit in-person interactions and workplace precautions that prioritize health of our employees.
Innovating for a Healthier World & Overwhelming Commitment to “For the Better”

R&D Team in Taicang working during Chinese New Year

Working overtime to support COVID-19 testing in Denmark

Ramping instrument production in Hopkinton, MA

Leveraging Global Capabilities to Respond Rapidly to evolving customer needs

Legend:  
- Instruments / Automation  
- Reagents / Kits / Collection Device  
- Both
**COMPLETE WORKFLOW FOR RT-PCR TESTING**

**PCR Testing:** Plug-and-Play & Complete, Automated SARS-CoV-2 PCR Detection Workflows

**RNA SAMPLE PREP**
- JANUS® G3 Primary Sample Reformatter

**RNA EXTRACTION**
- chemagic™ Viral extraction kit + chemagic™ 360 instrument
- PreNATII instrument & kits

**PCR SETUP**
- JANUS® G3 PCR Workstation

**REAL-TIME PCR**
- SARS-CoV-2 PCR assay
- EURORealTime SARS-CoV-2

**Comments:**
- Our workflows can use nasal swabs or saliva
- Complete workflow solutions enhance sample control and integrity
- Scaling manufacturing capacity: SARS-CoV-2 PCR Assay approved in 30+ countries

* capacity as of May 5th
**COMPLETE WORKFLOW FOR ANTIBODY TESTING**

**Antibody Testing:** Automated ELISA & POC Workflows

**SAMPLE COLLECTION**
- Plasma & Serum
- Dried Blood Spots(1)

**TEST**
- Anti-SARS-CoV-2 IgA + IgG ELISAs (S1 Domain)
- **Anti-SARS-CoV-2 IgG (EUA)**

**AUTOMATION**
- EUROLabWorkstation

**PerkinElmer Offerings**

**ELISA**
- Plasma & Serum
  - Dried Blood Spots(1)

**ChLIA**
- Finger Prick(1)
  - Blood or Plasma & Serum

**Lateral Flow**
- SARS-CoV-2 Antibody Detection Kits: IgM, IgG, IgM + IgG
- IgM+IgG and IgA antibodies(1)

**Comments:**
(1) Under Validation

**ELISA:** S1-Protein capacity of 10M tests/mo by end of May. CE-mark “designer” N-Protein ELISA launched

**ELISA:** ELW is one of the largest & fastest ELISA systems available; ANY OPEN ELISA system can run the EI S1 tests.

* capacity as of May 5th
**CAPABILITIES EXTEND BEYOND DIAGNOSTICS**

**Innovation in Other Segments**

**Applied**
Spectrum Two+ Hand Sanitizer Analyzer

Fast and reliable quantification of Ethanol and Isopropanol in hand sanitizer to ensure adherence with WHO and FDA-approved formulations

**Discovery**
ALPHA + HTRF Assays for Virology Research

Over 100 innovative tests to enable researchers to investigate innate and adaptive immunity, viral detection and life cycle, and cellular death induction

**Informatics**
New Clinical Study Template

Template was built into Signals Medical Review to help qualify antibodies. Additional solutions are being adopted to support COVID-19 analysis and promote drug discovery
While the PerkinElmer COVID-19 story and learnings from this crisis are far from complete…

**LOOKING AHEAD…**

Our guiding principles have been…

1. **Keep our employees and company safe**
2. **Utilize our expansive capabilities to join the fight against COVID-19**
3. **Serve all our customers with excellence**
4. **Emerge from this crisis a stronger company**

Breadth of capabilities puts PKI in a unique position to help…

**Diagnostics**
- Automation/Liquid Handling
- RNA Extraction
- RT-PCR + Antibody kits and validated workflows

**Discovery & Analytical Solutions**
- IL & cytokine research reagents
- Informatics solutions
- Hand-sanitizer QA/QC

We are honing and developing new skills as an organization…

- Demonstrating in real-time that we can innovate & deliver solutions to customers with more rapid speed
- Empowering leaders to lead by removing approval layers and allowing them to make decisions that effect their customers and businesses

We are confident PerkinElmer will emerge from this crisis a stronger company
INNOVATING for a healthier world

Bryan Kipp | Vice President, Investor Relations | 781.663.5583 | bryan.kipp@perkinelmer.com